Featured Company Product Pipelines

• IDM Pharma (France / USA)
• Sunesis Pharmaceuticals (USA)
• Daiichi Sankyo (Japan)

Special Pipeline

• Glucagon-like peptide-1 (GLP-1) Analogs Pipeline

• Focus on cancer immunotherapy after merge of IDM with Epimmune in August 2005;
• Lead project Junovan® (a tripeptide vaccine) in phase III for osteosarcoma with anticipated submission of BLA and MAA in 2006;
• three phase II projects in bladder cancer, melanoma and NSCLC;
• partnership with Sanofi-Aventis for Uvidem® (autologus dendritic cells loaded with lysates from melanoma cell lines);
• dendritic cell vaccine Collidem® in phase I for advanced colorectal cancer
  

Sunesis Pharmaceuticals (USA)

• Licensed-in CDK inhibitor and S-phase cell cycle inhibitor in clinical development stage for cancer;
• Aurora kinase inhibitor from own drug discovery scheduled for IND in 2006;
• Proprietarty technology platform in fragment-based drug discovery (Tethering®);
• Drug discovery collaborations in cancer and non-cancer indications with Biogen IDEC, J&J and Merck utilizing Tethering®;
  

Daiichi Sankyo (Japan)

• Filled global drug development pipeline after recently completed merger;
• Small molecules as predominant product category, but also 10 biologics projects (4 peptides, 2 proteins, 2 antibodies, one vaccine and gene therapy approach);
• Major therapeutic area in cardiovascular and metabolic diseases;
• Weak oncology pipeline;
• Phase I long-acting neuraminidase inhibitor project in antibiotic-dominated infectious disease area pipeline;
• Other prioritized disease areas inflammation and bone metabolism
  

Glucagon-like peptide-1 (GLP-1) Analogs Pipeline

• First product with twice daily dosing launched in the US by Lilly in June 2005 with sales of US$ 74.6 mln;
• challenged by once-daily dosing of Novo Nordisk's GLP-1 analog, but countered by Lilly with once-weekly drug delivery solution;
• injectable sustained release formulations and nasal delivery of GLP-1 further down in the pipeline;
• next generation with fusion proteins of GLP-1 with large carrier proteins
• potential other uses of GLP-1 and analogs in irritable bowel syndrome and congestive heart failure